CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Supernus Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Supernus Pharmaceuticals Inc
9715 Key West Avenue
Phone: (301) 838-2500p:301 838-2500 ROCKVILLE, MD  20850  United States Ticker: SUPNSUPN
Business Summary
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Its products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO, and MYOBLOC. Qelbree is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older. GOCOVRI extended-release capsules are medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy. It is also involved in developing product candidates in neurology and psychiatry, including SPN-817 (huperzine A), SPN-820 (NV-5138), and SPN-443.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Charles W.Newhall 80 8/10/2016 1/1/2005
President, Chief Executive Officer, Secretary, Director Jack A.Khattar 63 1/1/2005 1/1/2005
Chief Financial Officer, Senior Vice President Timothy C.Dec 66 8/23/2021 8/23/2021
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Sage Therapeutics GmbH c/o Cormoran GmbH Am Zirkus 2 Berlin Germany
Sage Therapeutics Ltd. 280 Bishopsgate London United Kingdom
Adamas Pharmaceuticals Inc 1900 Powell St., Suite 1000 EMERYVILLE CA United States
SAGE Therapeutics Inc 55 Cambridge Parkway CAMBRIDGE MA United States

Business Names
Business Name
Adamas Holdings, LLC
Adamas Operations, LLC
Adamas Pharmaceuticals Inc
15 additional Business Names available in full report.

General Information
Number of Employees: 778 (As of 12/31/2025)
Outstanding Shares: 57,581,712 (As of 2/24/2026)
Shareholders: 15
Stock Exchange: NASD
Federal Tax Id: 202590184
Fax Number: (302) 636-5454


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 11, 2026